Analysis of the relationship between body composition and the pharmacokinetics of panitumumab in the treatment of localized squamous cell carcinoma of the anus - An ancillary study of the FFCD0904 phase I and II trial.

Fiche publication

Date publication

mars 2026

Journal

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEN ABDELGHANI Meher , Pr LEPAGE Côme

Tous les auteurs :
Lobet S, Ternant D, Lepage C, Le Malicot K, Azzopardi N, Dolly A, Nguyen F, Lagogué L, Bazire L, Lemanski C, Martin-Babau J, Lièvre A, De la Fouchardière C, Ben Abdelghani M, Paintaud G, Aparicio T, Vendrely V, Lecomte T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41865627

Résumé

Cancer-related cachexia alters body composition (BC) and organ function, potentially affecting drug pharmacokinetics (PK).This ancillary study of the FFCD0904 phase I/II trial, which evaluated panitumumab -based radiochemotherapy in localized squamous cell carcinoma (SCC) of the anus, explored association between panitumumab PK, BC and its effects.